Importantly, a combination of anti-CD137/PD-1/CTLA4 mAbs was shown to be therapeutically efficacious (and sometimes curative) in all of 4 mouse models investigated when delivered to the tumor microenvironment, and the efficacy was further increased by also including a mAb to CD19 [27]. Here, CTLA4 is linked to neoplasm.